(Q38005459)

26 August 2017

title

CCR5 inhibitors: emergence, success, and challenges (English)

1 reference

26 August 2017

Kenji Maeda

1

1 reference

26 August 2017

Debananda Das

series ordinal

2

1 reference

26 August 2017

Hirotomo Nakata

series ordinal

3

1 reference

26 August 2017

Hiroaki Mitsuya

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

25 April 2012

1 reference

Expert Opinion on Emerging Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

17

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

135-145

1 reference

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

The survival benefits of AIDS treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

HIV and AIDS: 20 years of science

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

gp120: Biologic aspects of structural features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Novel therapies based on mechanisms of HIV-1 cell entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

HIV entry and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Chemokine receptors: keys to AIDS pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Chemokine receptors and the clinical course of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

CCR5 deficiency increases risk of symptomatic West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Chemokine polymorphisms and lymphoma: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

European guidelines on the clinical management of HIV-1 tropism testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Clinical utility of maraviroc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

HIV-1 entry inhibitors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Structural and molecular interactions of CCR5 inhibitors with CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.673584

10.1517/14728214.2012.673584

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference